Study of MLN8237 in Participants With Advanced Hematological Malignancies
Public ClinicalTrials.gov record NCT00697346. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-label, Phase 1 Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Patients With Advanced Hematological Malignancies
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is an open-label, multicenter, phase 1 study of MLN8237 in participants with advanced hematological malignancies for whom there are limited standard treatment options.
Study identification
- NCT ID
- NCT00697346
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 58 participants
Conditions and interventions
Conditions
- B-cell Follicular Lymphoma
- B-cell Marginal Zone Lymphoma
- Diffuse Large B-cell Lymphoma
- B-cell Mantle Cell Lymphoma
- B-cell Small Lymphocytic Lymphoma
- B-Cell Chronic Lymphocytic Leukemia
- Multiple Myeloma
- Waldenstrom's Macroglobulinemia
- Noncutaneous Peripheral T-cell Lymphoma Not Otherwise Specified
- Angioimmunoblastic T-cell Lymphoma
- Anaplastic Large Cell Lymphoma
- Enteropathy Associated T-cell Lymphoma
- NK Lymphoma
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 11, 2008 (Actual)
- Primary completion
- Oct 1, 2016 (Actual)
- Completion
- Oct 19, 2016 (Actual)
- Last update posted
- May 31, 2019
2008 – 2016
United States locations
- U.S. sites
- 10
- U.S. states
- 9
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Scottsdale | Arizona | — | — |
| Not listed | Lexington | Kentucky | — | — |
| Not listed | Baltimore | Maryland | — | — |
| Not listed | Omaha | Nebraska | — | — |
| Not listed | Hackensack | New Jersey | — | — |
| Not listed | Buffalo | New York | — | — |
| Not listed | Chapel Hill | North Carolina | — | — |
| Not listed | Nashville | Tennessee | — | — |
| Not listed | Houston | Texas | — | — |
| Not listed | San Antonio | Texas | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00697346, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 31, 2019 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00697346 live on ClinicalTrials.gov.